Nanofiber-coated drug eluting stent for the stabilization of mast cells

Pharmaceutical Research

Volumn 31, Issue 9, 2014, Pages 2463-2478

  Oh, Byeongtaek ^a   Lee, Chi H ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Edaravone (EDV); mast cells; nanofiber; nitric oxide (NO); reactive oxygen species (ROS)

Indexed keywords

NANOFIBER; NITRIC OXIDE DONOR; PHENAZONE; PHENYLMETHYLPYRAZOLONE; REACTIVE OXYGEN METABOLITE; SCAVENGER;

ANALOGS AND DERIVATIVES; CELL LINE; CHEMISTRY; CYTOLOGY; DEGRANULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG ELUTING STENT; HUMAN; IMMUNOLOGY; MAST CELL;

ANTIPYRINE; CELL DEGRANULATION; CELL LINE; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; FREE RADICAL SCAVENGERS; HUMANS; MAST CELLS; NANOFIBERS; NITRIC OXIDE DONORS; REACTIVE OXYGEN SPECIES;

EID: 84896440103     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1341-3     Document Type: Article

References (44)

1. Kabir AM, Selvarajah A, Seifalian AM. How safe and how good are drug-eluting stents? Future Cardiol. 2011;7:251-70.
2. Teirstein PS. Drug-eluting stent restenosis: an uncommon yet pervasive problem. Circulation. 2010;122:5-7.
3. Shirota T, Yasui H, Shimokawa H, Matsuda T. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials. 2003;24:2295-302.
4. Stefanadis C, Toutouzas K, Tsiamis E, Vlachopoulos C, Kallikazaros I, Stratos C, et al. Stents covered by autologous venous grafts: feasibility and immediate and long-term results. Am Heart J. 2000;139:437-45.
5. Farhatnia Y, Tan A, Motiwala A, Cousins BG, Seifalian AM. Evolution of covered stents in the contemporary era: clinical application, materials and manufacturing strategies using nanotechnology. Biotechnol Adv. 2013;31:524-42.
6. Oh B, Lee CH. Nanofiber for cardiovascular tissue engineering. Expert Opin Drug Deliv. 2013;10:1565-82.
7. Chatterjea D, Wetzel A, Mack M, Engblom C, Allen J, Mora-Solano C, et al. Mast cell degranulation mediates compound 48/80-induced hyperalgesia in mice. Biochem Biophys Res Commun. 2012;425:237-43.
8. Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension. 2009;53:1041-7.
9. Tahara K, Tadokoro S, Yamamoto H, Kawashima Y, Hirashima N. The suppression of IgE-mediated histamine release from mast cells following exocytic exclusion of biodegradable polymeric nanoparticles. Biomaterials. 2012;33:343-51.
10. Xu JM, Shi GP. Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev. 2012;33:71-108.
11. Botand I, Biessen EA. Mast cells in atherosclerosis. Thromb Haemost. 2011;106:820-6.
12. Lebduska P, Korb J, Tumova M, Heneberg P, Draber P. Topography of signaling molecules as detected by electron microscopy on plasma membrane sheets isolated from non-adherent mast cells. J Immunol Methods. 2007;328:139-51.
13. Brieger K, Schiavone S, Miller Jr FJ, Krause KH. Reactive oxygen species: from health to disease. Swiss Med Wkly. 2012;142:w13659.
14. Kirkinezos IG, Moraes CT. Reactive oxygen species and mitochondrial diseases. Semin Cell Dev Biol. 2001;12:449-57.
15. Swindleand EJ, Metcalfe DD. The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev. 2007;217:186-205.
16. Hulsmans M, Van Dooren E, Holvoet P. Mitochondrial reactive oxygen species and risk of atherosclerosis. Curr Atheroscler Rep. 2012;14:264-76.
17. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000;87:179-83.
18. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-14.
19. Yoo JW, Acharya G, Lee CH. In vivo evaluation of vaginal films for mucosal delivery of nitric oxide. Biomaterials. 2009;30:3978-85.
20. Koranteng RD, Dearman RJ, Kimber I, Coleman JW. Phenotypic variation in mast cell responsiveness to the inhibitory action of nitric oxide. Inflamm Res. 2000;49:240-6.
21. Iikura M, Takaishi T, Hirai K, Yamada H, Iida M, Koshino T, et al. Exogenous nitric oxide regulates the degranulation of human basophils and rat peritoneal mast cells. Int Arch Allergy Immunol. 1998;115:129-36.
22. Eastmond NC, Banks EM, Coleman JW. Nitric oxide inhibits IgE-mediated degranulation of mast cells and is the principal intermediate in IFN-gamma-induced suppression of exocytosis. J Immunol. 1997;159:1444-50.
23. Yip K, Leung F, Huang Y, Lau H. Inhibition of anti-IgE mediated human mast cell activation by NO donors is dependent on their NO release kinetics. Br J Pharmacol. 2009;156:1279-86.
24. Davis BJ, Flanagan BF, Gilfillan AM, Metcalfe DD, Coleman JW. Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells. J Immunol. 2004;173:6914-20.
25. Alef MJ, Tzeng E, Zuckerbraun BS. Nitric oxide and nitrite-based therapeutic opportunities in intimal hyperplasia. Nitric Oxide. 2012;26:285-94.
26. Acharya G, Lee CH, Lee Y. Optimization of cardiovascular stent against restenosis: factorial design-based statistical analysis of polymer coating conditions. PLoS One. 2012;7:e43100. United States.
27. Oh B, Lee CH. Advanced cardiovascular stent coated with nanofiber. Mol Pharm. 2013;10:4432-42.
28. Xu C, Wang Y. Cross-linked demineralized dentin maintains its mechanical stability when challenged by bacterial collagenase. J Biomed Mater Res B Appl Biomater. 2011;96:242-8.
29. Yoo JW, Lee JS, Lee CH. Characterization of nitric oxide-releasing microparticles for the mucosal delivery. J Biomed Mater Res A. 2010;92:1233-43.
30. Yoo JW, Giri N, Lee CH. pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharm. 2011;403:262-7.
31. Mokudai T, Nakamura K, Kanno T, Niwano Y. Presence of hydrogen peroxide, a source of hydroxyl radicals, in acid electrolyzed water. PLOS ONE. 2012;7:e46392.
32. Yunos DM, Ahmad Z, Salih V, Boccaccini AR. Stratified scaffolds for osteochondral tissue engineering applications: electrospun PDLLA nanofibre coated Bioglass(R)-derived foams. J Biomater Appl. 2013;27:537-51.
33. Acharya G, Hopkins RA, Lee CH. Advanced polymeric matrix for valvular complications. J Biomed Mater Res A. 2012;100:1151-9.
34. Bhattarai N, Li Z, Edmondson D, Zhang M. Alginate-based nanofibrous scaffolds: structural, mechanical, and biological properties. Adv Mater. 2006;18:1463-7.
35. Bhattarai M, Zhang M. Controlled synthesis and structural stability of alginate-based nanofibers. Nanotechnology. 2007;18:455601.
36. Noor JI, Ikeda T, Ueda Y, Ikenoue T. A free radical scavenger, edaravone, inhibits lipid peroxidation and the production of nitric oxide in hypoxic-ischemic brain damage of neonatal rats. Am J Obstet Gynecol. 2005;193:1703-8.
37. Nakagawa H, Ohyama R, Kimata A, Suzuki T, Miyata N. Hydroxyl radical scavenging by edaravone derivatives: efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5-pyrazolone with an intramolecular base. Bioorg Med Chem Lett. 2006;16:5939-42.
38. Suzuki Y, Yoshimaru T, Inoue T, Ra C. Discrete generations of intracellular hydrogen peroxide and superoxide in antigen-stimulated mast cells: reciprocal regulation of store-operated Ca2+ channel activity. Mol Immunol. 2009;46:2200-9.
39. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41:40-59.
40. Curzonand G, Green AR. Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol. 1970;39:653-5.
41. Dearman RJ, Skinner RA, Deakin N, Shaw D, Kimber I. Evaluation of an in vitro method for the measurement of specific IgE antibody responses: the rat basophilic leukemia (RBL) cell assay. Toxicology. 2005;206:195-205.
42. Suzuki Y, Yoshimaru T, Yamashita K, Matsui T, Yamaki M, Shimizu K. Exposure of RBL-2H3 mast cells to Ag(+) induces cell degranulation and mediator release. Biochem Biophys Res Commun. 2001;283:707-14.
43. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007;13:719-24.
44. Swindle EJ, Metcalfe DD, Coleman JW. Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide. J Biol Chem. 2004;279:48751-9.